Journal
JOURNAL OF IMMUNOLOGY
Volume 187, Issue 6, Pages 3391-3401Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1101421
Keywords
-
Categories
Funding
- HIV Vaccine Trials Network and Statistical Center for HIV/AIDS Research Prevention
- National Institutes of Health Division of AIDS (National Institute of Allergy and Infectious Diseases) [U01 AI068614, U01 AI068618, U01 AI068635]
- University of Washington Center for AIDS Research
- National Institutes of Health [P30 AI027757]
Ask authors/readers for more resources
Many candidate HIV vaccines are designed to primarily elicit T cell responses. Although repeated immunization with the same vaccine boosts Ab responses, the benefit for T cell responses is ill defined. We compared two immunization regimens that include the same recombinant adenoviral serotype 5 (rAd5) boost. Repeated homologous rAd5 immunization fails to increase T cell responses, but increases gp140 Ab responses 10-fold. DNA prime, as compared with rAd5 prime, directs long-term memory CD8(+) T cells toward a terminally differentiated effector memory phenotype with cytotoxic potential. Based on the kinetics of activated cells measured directly ex vivo, the DNA vaccination primes for both CD4(+) and CD8(+) T cells, despite the lack of detection of the latter until after the boost. These results suggest that heterologous prime-boost combinations have distinct immunological advantages over homologous prime-boosts and suggest that the effect of DNA on subsequent boosting may not be easily detectable directly after the DNA vaccination. The Journal of Immunology, 2011, 187: 3391-3401.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available